Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy

Enfuvirtide (T20), is the first HIV fusion inhibitor approved for treatment of HIV/AIDS patients who fail to respond to the current antiretroviral drugs. However, its clinical application is limited because of short half-life, drug resistance and cross-reactivity with the preexisting antibodies in H...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiaojie, Zhu, Yun, Ye, Sheng, Wang, Qian, Xu, Wei, Su, Shan, Sun, Zhiwu, Yu, Fei, Liu, Qi, Wang, Chao, Zhang, Tianhong, Zhang, Zhenqing, Zhang, Xiaoyan, Xu, Jianqing, Du, Lanying, Liu, Keliang, Lu, Lu, Zhang, Rongguang, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541410/
https://www.ncbi.nlm.nih.gov/pubmed/26286358
http://dx.doi.org/10.1038/srep13028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541410/
https://www.ncbi.nlm.nih.gov/pubmed/26286358
http://dx.doi.org/10.1038/srep13028

Ejemplares similares